9I制作厂免费

Paying Attention to Small Decisions Pays Off?

Published: 20 November 2013

In continuing my coverage of the ideas of Jeroen De Flander in The Execution Shortcut, let me first introduce the problem of missing prioritization information. It describes a situation in which...

Talking Management with Karl Moore: How GE Management Practices Have Changed

Published: 20 November 2013

Professor Karl Moore of the Desautels Faculty of Management at 9I制作厂免费 speaks to Tom Gentile, CEO of GE Healthcare Systems. Read full transcript: The Globe and Mail, November 19, 2013

Premium Drives Dating, Music Engagement, Revs

Published: 20 November 2013

At the Mapping Mobile Conference at New York University鈥檚 Stern School of Business last week, panelists spoke about everything from consumer research to dating sites. One dominant takeaway is that...

Success Is What You Make It

Published: 20 November 2013

What is success and how do you measure it? The experiences of a diversegroup of workers show how 鈥 and how much 鈥 they managed to balance career success with family responsibilities. Those who...

Montreal Case Competition Teaches Chemistry & MBA Students Sustainability for the Real World

Published: 19 November 2013

Last Fall, the Marcel Desautels Institute for Integrated Management (MDIIM) and the 9I制作厂免费 Department of Chemistry in Montreal collaborated to offer MBA and Chemistry Students the opportunity to...

Seminar: Diane Bailey, University of Texas, Austin

Friday, November 22, 2013 10:00to11:30

Technology Choices: Why Occupations Differ in Their Embrace of New Technologies...

Who Is the Most Influential Living Management Thinker?

Published: 19 November 2013

The Thinkers50 2013 provides the answer. Described as the Oscars of Management Thinking, the global ranking is published every two years and is the essential guide to which thinkers and which ideas...

Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors

Published: 19 November 2013

Regado Biosciences, Inc. (RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today...

Pages

Back to top